Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

employee- and office-related expenses.

-- In the fourth quarter ended December 31, 2007, Sunesis recorded a $0.3

million additional restructuring charge as a result of the company's

reorganization and reduction in force in the third quarter of 2007.

For the year ended December 31, 2007, an aggregate of $1.6 million in

restructuring charges was recorded. Cash restructuring costs accounted

for approximately $1.1 million of the total $1.6 million restructuring

charge for the year.

-- Sunesis reported a net loss of $8.8 million for the fourth quarter of

2007 and of $38.8 million for the twelve-month period ended December

31, 2007, compared to a reported net loss of $9.0 million and $31.2

million, respectively, for the three-month and twelve-month periods

ended December 31, 2006.

-- In 2008, Sunesis expects net cash used in operating activities of

approximately $30 million - $35 million in the absence of any new

collaborations, compared to $34.5 million in 2007. A decrease in net

cash used in operating activities is anticipated primarily due to the

reorganization effected in August of last year, partially offset by

increased costs associated with clinical trial and other development

activities for SNS-595, SNS-032 and SNS-314.

Conference Call Information

Sunesis' management will host a conference call to review the results of the fourth quarter and the 2007 fiscal year today at 10:30 a.m. EDT. Individual and institutional investors can access the call via 877-604-9668 (U.S. and Canada) or 719-325-4904 (international). To access the live audio webcast or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://www.sunesis.com. Please log on to Sunesis' website severa
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... The report “Service Quality Management and Telco Customer ... - Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” defines ... forecasting of revenues. , Browse 152 market data ... TOC on “Service Quality Management (SQM) and Telco Customer ...
(Date:12/24/2014)... DALLAS and NEW YORK , ... a biopharmaceutical company advancing patient care in critical areas, announced ... of common stock, and warrants to purchase up to an ... of $4.00 per share and $.01 per warrant.  The warrants ...
(Date:12/24/2014)...   BioLife Solutions , Inc. (NASDAQ: BLFS ), ... hypothermic storage and cryopreservation freeze media ... tissues  ("BioLife" or the "Company"), today announced that it will ... 2015 (the "Annual Meeting"). Because the expected date ...
(Date:12/24/2014)... Louis, Missouri (PRWEB) December 23, 2014 GMO ... biotechnology company, Syngenta, are in the process of being consolidated ... case is In Re: Syngenta AG MIR 162 Corn Litigation, ... District of Kansas. , Management of the Syngenta GMO corn ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... , , BRISBANE, Calif., Aug. 6 ... the second quarter and six months ended June 30, 2009. ... million, or $0.81 per share, compared with a net loss of $29.6 million, ... , Dan Welch, Chairman, Chief Executive Officer and President of ...
... , EMERYVILLE, Calif., Aug. 6 ... John E. Sealander, AIA, ACHA, NCARB, LEED(R) AP, as a ... http://www.ratcliffarch.com ) provides a broad array ... clients throughout the Western United States. , , ...
... LEXINGTON, Ky. , Aug. 6 ... announced today that its scientists and collaborators from the Medical ... rat model of severe combined immunodeficiency, or SCID. The Transposagen ... of the immune system. Transposagen will be marketing SCID rats ...
Cached Biology Technology:InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 2InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 3InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 4InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 5InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 6InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 7InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 8InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 9InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 10InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 11InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 12InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 14InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 15Ratcliff Adds Architect John Sealander to Healthcare Practice Group 2Transposagen Creates a Rat Model of the Human Immune System 2Transposagen Creates a Rat Model of the Human Immune System 3
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric ... recent success of the Wocket™ smart wallet at CES 2015 in ... named as one of the "11 Hot Products at CES" in a ... CES So Far" by Newseveryday.com and "The top 10 gadgets from CES ...
(Date:1/22/2015)... Issued by Small Cap IR. In 2011, Nilson Report,s annual ... merchants on the leading payment cards rose to $135.3 billion ... prepaid cards reached 6.54 billion.  Eight million credit card users ... 2012, and credit and debit card fraud resulted in $11.27 ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... including scientists from Woods Hole Oceanographic Institution (WHOI), discovered ... Until now, sea ice was thought to block sunlight ... under the ice. The amount of phytoplankton growing ... the amount found in neighboring ice-free waters. The bloom ...
... exploring how proteins interact with crucial DNA sequences to ... biological events that may eventually be manipulated to provide ... regulatory elements in DNA called promoters and enhancers communicate ... over large genomic distances, hundreds of thousands of chemical ...
... Institute for the Environment researchers have helped open a new ... world,s coral reefs. Working with an international team, the ... Rob Dunbar and Steve Monismith found a way to ... Great Barrier Reef. The water inside the device can mimic ...
Cached Biology News:Scientists discover huge phytoplankton bloom in ice-covered waters 2Scientists discover huge phytoplankton bloom in ice-covered waters 3Manipulating chromatin loops to regulate genes may offer future treatments for blood diseases 2Stanford researchers help predict the oceans of the future with a mini-lab 2
... derivatives that have mutations in both the ... genes, which greatly enhances disulfide bond formation ... expression in Origami(DE3) yielded 10-fold more active ... overall expression levels were similar (1). Origami ...
Request Info...
Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
... kit contains 5 ml CELLection Dynabeads (4.5 ... the human epithelial antigen EpCAM and DNase ... log enrichment of epithelial tumour cells directly ... cells clumps can be enriched from bone ...
Biology Products: